Squarepoint
XERS icon

Squarepoint’s Xeris Biopharma Holdings XERS Stock Holding History

Squarepoint’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9M Sell
365,731
-248,819
-40% -$1.59M ﹤0.01% 2033
2026
Q1 		$3.56M Buy
614,550
+131,718
+27% +$873K ﹤0.01% 1752
2025
Q4 		$3.79M Sell
482,832
-196,249
-29% -$1.54M ﹤0.01% 1635
2025
Q3 		$5.53M Buy
679,081
+394,514
+139% +$2.62M 0.01% 1404
2025
Q2 		$1.33M Buy
284,567
+268,572
+1,679% +$1.23M ﹤0.01% 2413
2025
Q1 		$87.8K Sell
15,995
-24,774
-61% -$100K ﹤0.01% 4252
2024
Q4 		$138K Buy
40,769
+22,084
+118% +$71K ﹤0.01% 4601
2024
Q3 		$53.3K Buy
+18,685
New +$48K ﹤0.01% 3974
2022
Q3 		– Sell
-11,651
Closed -$18K – 3514
2022
Q2 		$18K Sell
11,651
-121,799
-91% -$257K ﹤0.01% 2778
2022
Q1 		$342K Buy
133,450
+119,567
+861% +$292K ﹤0.01% 2203
2021
Q4 		$41K Buy
13,883
+1,288
+10% +$2.78K ﹤0.01% 3049
2021
Q3 		$31K Sell
12,595
-20,008
-61% -$58.1K ﹤0.01% 2807
2021
Q2 		$133K Buy
+32,603
New +$124K ﹤0.01% 2963
2020
Q3 		– Sell
-45,809
Closed -$122K – 2887
2020
Q2 		$122K Buy
45,809
+28,973
+172% +$101K ﹤0.01% 1968
2020
Q1 		$33K Buy
+16,836
New +$72.4K ﹤0.01% 1753

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Squarepoint's XERS Position: Q2 2026 in Review

Squarepoint reduced its Xeris Biopharma Holdings (XERS) stake by 40% in Q2 2026, selling an estimated $1.59M and leaving 365,731 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

Squarepoint first reported a position in XERS in Q1 2020 and has held it in 15 quarters since. The position peaked at $5.53M in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Squarepoint held 365,731 shares of Xeris Biopharma Holdings worth $2.9M as of Q2 2026.
  • Squarepoint sold 248,819 Xeris Biopharma Holdings shares in Q2 2026, an estimated $1.59M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2033 holding.
  • Squarepoint first reported a position in Xeris Biopharma Holdings in Q1 2020 and has held it in 15 quarters since.
  • Squarepoint's Xeris Biopharma Holdings position peaked at $5.53M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.